12:00 AM
Sep 27, 1999
 |  BC Week In Review  |  Company News  |  Deals

Valentis, Boehringer Ingelheim deal

The companies will develop gene therapy products to treat rheumatoid arthritis (RA) using VLTS's gene delivery...

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >